RVPH REVIVA PHARMACEUTICALS HLDGS INC

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.

H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Format: Corporate update

Date/Time: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET for registered conference attendees

Location: Virtual

Registration Link:

About Reviva 

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD 

Investor Relations Contact:

LifeSci Advisors, LLC

Bruce Mackle



EN
05/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REVIVA PHARMACEUTICALS HLDGS INC

 PRESS RELEASE

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million...

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of...

 PRESS RELEASE

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offeri...

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the secur...

 PRESS RELEASE

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspect...

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking pla...

 PRESS RELEASE

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open...

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia – Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) --  Reviva ...

 PRESS RELEASE

Reviva to Participate in Upcoming Investor Conferences in May 2025

Reviva to Participate in Upcoming Investor Conferences in May 2025 CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences. Benchmark Healthcare House Call Virtual Investor Confere...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch